Future Treatment Options in Systemic Sclerosis-Potential Targets and Ongoing Clinical Trials

Area of Science:

• Immunology and Rheumatology
• Autoimmune Diseases
• Fibrotic Conditions

Background:

• Systemic sclerosis is a complex autoimmune connective tissue disease marked by vasculopathy and fibrosis.
• Current treatments for systemic sclerosis are often insufficient to halt disease progression.
• Immune cell mediators play a key role in the inflammatory processes of systemic sclerosis.

Purpose of the Study:

• To provide an overview of potential therapeutic targets for systemic sclerosis.
• To review the pipeline of future therapeutic options based on ongoing clinical trials.
• To highlight novel treatment strategies for managing systemic sclerosis.

Main Methods:

• Review of clinical trials investigating novel, unestablished treatment methods for systemic sclerosis.
• Identification of therapeutic targets based on increasing knowledge of disease pathogenesis.
• Analysis of drug trials targeting specific mediators and pathways involved in systemic sclerosis.

Main Results:

• Numerous drug trials are underway targeting key mediators such as CD28-CD80/86, CD19, CCL24, CD20, CD30, tumor necrosis factor (TNF), transforming growth factor β (TGF-β), B-cell activating factor (BAFF), lysophosphatidic acid receptor 1 (LPA1 receptor), soluble guanylate cyclase (sGC), Janus kinases (JAK), interleukin 6 (IL-6), endothelin receptor, and autotaxin.
• Early data from these clinical trials suggest significant potential for several new therapeutic options.
• Advancements in understanding disease processes are driving the development of targeted therapies.

Conclusions:

• Emerging therapeutic targets and ongoing clinical trials offer significant hope for improved systemic sclerosis treatment.
• Novel therapies targeting specific immune pathways and mediators show promise in halting disease progression.
• The future pipeline for systemic sclerosis treatment is robust, with multiple promising options on the horizon.